Mapping genetic alterations causing chemoresistance in cancer: Identifying the roads by tracking the drivers

Oncogene

Volumn 32, Issue 46, 2013, Pages 5315-5330

  Lonning P E ^a,b   Knappskog, S ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Chemoresistance; chemotherapy; DNA repair; germline; mutations; TP53

Indexed keywords

ANTHRACYCLINE; ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; CYTARABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; FLUDARABINE; PENTOSTATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; B CELL LYMPHOMA; CANCER PROGNOSIS; CELL CYCLE ARREST; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; DNA END JOINING REPAIR; DNA REPAIR; EXCISION REPAIR; GENE MAPPING; GENE MUTATION; GENETIC ANALYSIS; HETEROZYGOSITY; HUMAN; MISSENSE MUTATION; NEOPLASM; NONSENSE MUTATION; NUCLEAR LOCALIZATION SIGNAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECOMBINATION REPAIR; REVIEW; T CELL LEUKEMIA; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PROGNOSIS;

EID: 84888007767     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.48     Document Type: Review

References (284)

1. Schrohl AS, Meijer-van Gelder ME, Holten-Andersen MN, Christensen IJ, Look MP, Mouridsen HT et al. Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer. Clin Cancer Res 2006; 12: 7054-7058. (Pubitemid 44974503)
2. Sørensen NM, Bystrom P, Christensen IJ, Berglund A, Nielsen HJ, Brunner N et al. TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res 2007; 13: 4117-4122. (Pubitemid 47105974)
3. McGrogan BT, Gilmartin B, Camey DN, McCann A. Taxanes microtubules and chemoresistant breast cancer. Biochim Biophys Acta 2008; 1785: 96-132.
4. Lønning PE. Genes causing inherited cancer as beacons identifying the mechanisms of chemoresistance. Trends Mol Med 2004; 10: 113-118. (Pubitemid 38293346)
5. Lønning P. Study of suboptimum treatment response: lessons from breast cancer. Lancet Oncol 2003; 4: 177-185. (Pubitemid 36322308)
6. Lønning PE, Knappskog S, Staalesen V, Chrisanthar R, Lillehaug JR. Breast cancer prognostication and prediction in the postgenomic era. Ann Oncol 2007; 18: 1293-1306. (Pubitemid 47305001)
7. Rose C, Thorpe SM, Andersen KW, Pedersen BV, Mouridsen HT, Blichert-Toft M et al. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet 1985; 1: 16-19. (Pubitemid 15160544)
8. Lønning PE. Molecular basis for therapy resistance. Mol Oncol 2010; 4: 284-300.
9. Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 2003; 63: 6643-6650. (Pubitemid 37322942)
10. Dumont P, Leu JIJ, Della Pietra AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33: 357-365. (Pubitemid 36278852)
11. Ma YL, Yang JJ, Liu ZH, Zhang P, Yang Z, Wang Y et al. No significant association between the TP53 codon 72 polymorphism and breast cancer risk: a metaanalysis of 21 studies involving 24,063 subjects. Breast Cancer Res Treat 2011; 125: 201-205.
12. Geisler S, Lønning PE, Aas T, Johnsen H, Fluge O, Haugen DF et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001; 61: 2505-2512. (Pubitemid 32685830)
13. Sjö gren S, Inganä s M, Norberg T, Lindgren A, Nordgren H, Holmberg L et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996; 88: 173-182. (Pubitemid 26065829)
14. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996; 2: 985-991. (Pubitemid 26306836)
15. Lehmann S, Bykov VJN, Ali D, Andren O, Cherif H, Tidefelt U et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 2012; 30: 3633-3639.
16. Danks MK, Whipple DO, McPake CR, Lu DY, Harris LC. Differences in epitope accessibility of p53 monoclonal antibodies suggest at least three conformations or states of protein binding of p53 protein in human tumor cell lines. Cell Death Differ 1998; 5: 678-686. (Pubitemid 28391370)
17. Lambert JMR, Gorzov P, Veprintsev DB, Soderqvist M, Segerback D, Bergman J et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 2009; 15: 376-388.
18. Zenz T, Eichhorst B, Busch R, Denzel T, Habe S, Winkler D et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 4473-4479.
19. Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G et al. P53 gene deletion predicts for poor survival and nonresponse to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580-1589.
20. Diccianni MB, Yu J, Hsiao M, Mukherjee S, Shao L-E, Yu AL. Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood 1994; 84: 3105-3112. (Pubitemid 24328104)
21. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84: 3148-3157.
22. Preudhomme C, Dervite I, Wattel E, Vanrumbeke M, Flactif M, Lai JL et al. Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: a report of 48 cases. J Clin Oncol 1995; 13: 812-820.
23. Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 1997; 337: 529-534. (Pubitemid 27352019)
24. Geisler S, Borresen-Dale AL, Johnsen H, Aas T, Geisler J, Akslen LA et al. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 2003; 9: 5582-5588. (Pubitemid 37499478)
25. Chrisanthar R, Knappskog S, Lokkevik E, Anker G, Ostenstad B, Lundgren S et al. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLos One 2008; 3: e3062.
26. Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000; 6: 50-56. (Pubitemid 30064975)
27. Chrisanthar R, Knappskog S, Lokkevik E, Anker G, Ostenstad B, Lundgren S et al. Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. PLos One 2011; 6: e19249.
28. Fernandez-Cuesta L, Oakman C, Falagan-Lotsch P, Smoth KS, Quinaux E, Buyse M et al. Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline-or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res 2012; 14: 3.
29. Deissler H, Kafka A, Schuster E, Sauer G, Kreienberg R, Zeillinger R. Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response. Oncol Rep 2004; 11: 1281-1286.
30. Oshima K, Naoi Y, Kishi K, Nakamura Y, Iwamoto T, Shimazu K et al. Gene expression signature of TP53 but not its mutation status predicts response to sequential paclitaxel and 5-FU/epirubicin/cyclophosphamide in human breast cancer. Cancer Lett 2011; 307: 149-157.
31. Lehmann-Che J, Andre F, Desmedt C, Mazouni C, Giacchetti S, Turpin E et al. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. Oncologist 2010; 15: 246-252.
32. Song SS, Xing GC, Yuan L, Wang J, Wang S, Yin YX et al. N-methylpurine DNA glycosylase inhibits p53-mediated cell cycle arrest and coordinates with p53 to determine sensitivity to alkylating agents. Cell Res 2012; 22: 1285-1303.
33. Bonnefoi H, Piccart M, Bogaerts J, Mauriac L, Fumoleau P, Brain E et al. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol 2011; 12: 527-539.
34. Righetti SC, DellaTorre G, Pilotti S, Menard S, Ottone F, Colnaghi MI et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996; 56: 689-693. (Pubitemid 26055453)
35. Lavarino C, Pilotti S, Oggionni M, Gatti L, Perego P, Bresciani G et al. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 2000; 18: 3936-3945.
36. Kandioler D, Stamatis G, Eberhardt W, Kappel S, Zochbauer-Muller S, Kuhrer I et al. Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer. J Thorac Cardiovasc Surg 2008; 135: 1036-1041. (Pubitemid 351622069)
37. Kandioler-Eckersberger D, Kappel S, Mittlbock M, Dekan G, Ludwig C, Janschek E et al. The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer. J Thorac Cardiovasc Surg 1999; 117: 744-750. (Pubitemid 29163079)
38. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006; 6: 909-923. (Pubitemid 44862676)
39. Morselli E, Tasdemir E, Maiuri MC, Galluzzi L, Kepp O, Criollo A et al. Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle 2008; 7: 3056-3061.
40. Vaseva AV, Marchenko ND, Ji K, Tsirka SE, Holzmann S, Moll UM. p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell 2012; 149: 1536-1548.
41. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002; 109: 335-346. (Pubitemid 34606876)
42. Jackson JG, Pant V, Li Q, Chang LL, Quintas-Cardama A, Garza D et al. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 2012; 21: 793-806.
43. Smeenk L, van Heeringen SJ, Koeppel M, Gilbert B, Janssen-Megens E, Stunnenberg HG et al. Role of p53 serine 46 in p53 target gene regulation. Plos One 2011; 6: 3.
44. Feng LJ, Hollstein M, Xu Y. Ser46 phosphorylation regulates p53-dependent apoptosis and replicative senescence. Cell Cycle 2006; 5: 2812-2819. (Pubitemid 44901744)
45. Mayo LD, Seo YR, Jackson MW, Smith ML, Guzman JR, Korgaonkar CK et al. Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified. J Biol Chem 2005; 280: 25953-25959. (Pubitemid 41022185)
46. Morachis JM, Murawsky CM, Emerson BM. Regulation of the p53 transcriptional response by structurally diverse core promoters. Genes Dev 2010; 24: 135-147.
47. Qian H, Wang T, Naumovski L, Lopez CD, Brachmann RK. Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites. Oncogene 2002; 21: 7901-7911. (Pubitemid 35398849)
48. Zhang XP, Liu F, Wang W. Two-phase dynamics of p53 in the DNA damage response. Proc Natl Acad Sci USA 2011; 108: 8990-8995.
49. Jemaa M, Galluzzi L, Kepp O, Boileve A, Lissa D, Senovilla L et al. Preferential killing of p53-deficient cancer cells by reversine. Cell Cycle 2012; 11: 2149-2158.
50. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev 2012; 26: 1268-1286.
51. Song H, Xu Y. Gain of function of p53 cancer mutants in disrupting critical DNA damage response pathways. Cell Cycle 2007; 6: 1570-1573. (Pubitemid 47327942)
52. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer D, Schuler M et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004; 303: 1010-1014. (Pubitemid 38209704)
53. Chipuk JE, Green DR. p53's believe it or not: Lessons on transcription-independent death. J Clin Immunol 2003; 23: 355-361. (Pubitemid 37083189)
54. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005; 19: 2122-2137. (Pubitemid 41330315)
55. Baumbusch LO, Myhre S, Langerod A, Bergamaschi A, Geisler SB, Lonning PE et al. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters. Mol Cancer 2006; 5: 47.
56. Bourdon JC, Khoury MP, Diot A, Baker L, Fernandes K, Aoubala M et al. p53 mutant breast cancer patients expressing p53 gamma have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Res 2011; 13: 1.
57. Li TY, Kon N, Jiang L, Tan MJ, Ludwig T, Zhao YM et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012; 149: 1269-1283.
58. Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 2011; 145: 571-583.
59. Shiloh Y. ATM and ATR: networking cellular responses to DNA damage. Curr Opin Genet Develop 2001; 11: 71-77. (Pubitemid 32119281)
60. Gurley KE, Kemp CJ. Ataxia-telangiectasia mutated is not required for p53 induction and apoptosis in irradiated epithelial tissues. Mol Cancer Res 2007; 5: 1312-1318.
61. Jallepalli PV, Lengauer C, Vogelstein B, Bunz F. The Chk2 tumor suppressor is not required for p53 responses in human cancer cells. J Biol Chem 2003; 278: 20475-20479. (Pubitemid 36806343)
62. Hirao A, Cheung A, Duncan G, Girard PM, Elia AJ, Wakeham A et al. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol 2002; 22: 6521-6532.
63. Ding H, Mao C, Li SM, Liu Q, Lin L, Chen Q. Lack of association between ATM C.1066-6T4G mutation and breast cancer risk: a meta-analysis of 8831 cases and 4957 controls. Breast Cancer Res Treat 2011; 125(2): 473-477.
64. Tavtigian SV, Oefner PJ, Babikyan D, Hartmann A, Healey S, Le Calvez-Kelm F et al. Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. Am J Hum Genet 2009; 85: 427-446.
65. Morrell D, Cromartie E, Swift M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J Natl Cancer Inst 1986; 77: 89-92. (Pubitemid 16077187)
66. Micol R, Ben Slama L, Suarez F, Le Mignot L, Beaute J, Mahlaoui N et al. Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype. J Allergy Clin Immunol 2011; 128: 382-U400.
67. Knappskog S, Chrisanthar R, Lokkevik E, Anker G, Ostenstad B, Lundgren S et al. Low expression levels of ATM may substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Res 2012; 14: R47.
68. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DCR, Shannon KE et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999; 286: 2528-2531.
69. Evans DG, Wu CL, Birch JM. BRCA2: a cause of Li-Fraumeni-like syndrome. J Med Genet 2008; 45: 62-63.
70. Consortium TCBCC-C. CHEK2 1100delC ans susceptibility to breast cancer: a collaborative analysis involving 10 860 breast cancer cases and 9065 controls from 10 studies. Am J Hum Genet 2004; 74: 1175-1182.
71. Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004; 75: 1131-1135. (Pubitemid 39532081)
72. Staalesen V, Falck J, Geisler S, Bartkova J, Borresen-Dale AL, Lukas J et al. Alternative splicing and mutation status of CHEK2 in stage III breast cancer. Oncogene 2004; 23: 8535-8544. (Pubitemid 39540804)
73. Yoon H, Liyanarachchi S, Wright FA, Davuluri R, Lockman JC, de la Chapelle A et al. Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53. Proc Natl Acad Sci USA 2002; 99: 15632-15637. (Pubitemid 35403983)
74. Kannan K, Amariglio N, Rechavi G, Jakob-Hirsch J, Kela I, Kaminski N et al. DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene 2001; 20: 2225-2234. (Pubitemid 32531280)
75. Staalesen V, Leirvaag B, Lillehaug JR, Lonning PE. Genetic and epigenetic changes in p21 and p21B do not correlate with resistance to doxorubicin or mitomycin and 5-fluorouracil in locally advanced breast cancer. Clin Cancer Res 2004; 10: 3438-3443. (Pubitemid 38685450)
76. Knappskog S, Chrisanthar R, Staalesen V, Borresen-Dale AL, Gram IT, Lillehaug JR et al. Mutations and polymorphisms of the p21B transcript in breast cancer. Int J Cancer 2007; 121: 908-910. (Pubitemid 47106224)
77. Zenz T, Mohr J, Eldering E, Kater AP, Buhler A, Kienle D et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 2009; 113: 3801-3808.
78. Allocati N, Di Ilio C, De Laurenzi V. p63/p73 in the control of cell cycle and cell death. Exper Cell Res 2012; 318: 1285-1290.
79. Brunner HG, Hamel BCJ, van Bokhoven H. P63 gene mutations and human developmental syndromes. Am J Med Genet 2002; 112: 284-290.
80. Stiewe T. The p53 family in differentiation and tumorigenesis. Nat Rev Cancer 2007; 7: 165-168.
81. Tomasini R, Tsuchihara K, Wilhelm M, Fujitani M, Rufini A, Cheung CC et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev 2008; 22: 2677-2691.
82. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG. Chemosensitivity linked to p73 function. Cancer Cell. 2003; 3: 403-410. (Pubitemid 38340308)
83. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003; 3: 387-402. (Pubitemid 38340307)
84. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002; 416: 560-564. (Pubitemid 34288861)
85. Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 2007; 117: 1370-1380. (Pubitemid 46718425)
86. Al-Bahlani S, Fraser M, Wong AYC, Sayan BS, Bergeron R, Melino G et al. P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism. Oncogene 2011; 30: 4219-4230.
87. Concin N, Hofstetter G, Berger A, Gehmacher A, Reimer D, Watrowski R et al. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: Evidence for a crucial p53-p73 cross-talk in vivo. Clin Cancer Res 2005; 11: 8372-8383. (Pubitemid 41746950)
88. Marine JC, Jochemsen AG. Mdmx and Mdm2-Brothers in arms? Cell Cycle 2004; 3: 900-904.
89. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119: 591-602. (Pubitemid 39535748)
90. Knappskog S, Bjornslett M, Myklebust LM, Huijts PE, Vreeswijk MP, Edvardsen H et al. The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer Cell 2011; 19: 273-282.
91. Knappskog S, Trovik J, Marcickiewicz J, Tingulstad S, Staff AC, TECsg MoMa et al. SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer. Eur J Cancer 2012; 48: 1988-1996.
92. Zauberman A, Flusberg D, Haupt Y, Barak Y, Oren M. A. Functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res 1995; 23: 2584-2592.
93. Chang CJ, Freeman DJ, Wu H. PTEN regulates Mdm2 expression through the P1 promoter. J Biol Chem 2004; 279: 29841-29848. (Pubitemid 38915868)
94. Gajjar M, Candeias MM, Malbert-Colas L, Mazars A, Fujita J, Olivares-Illana V et al. The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage. Cancer Cell 2012; 21: 25-35.
95. Atwal GS, Kirchhoff T, Bond EE, Monagna M, Menin C, Bertorelle R et al. Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene. Proc Natl Acad SciUSA 2009; 106: 10236-10241.
96. Xiao Z-X, Chen J, Levine AJ, Modjtahedl N, Xing J, Sellers WR et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995; 375: 694-698.
97. Martin K, Trouche D, Hagemeier C, Sørensen TS, La Thangue NE, Kouzarides T. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 1995; 375: 691-694.
98. Ray RM, Bhattacharya S, Johnson LR. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73-and E2F1-mediated expression of PUMA and Siva-1. Apoptosis 2011; 16: 35-44.
99. Sirvent N, Coindre JM, Maire G, Hostein I, Keslair F, Guillou L et al. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffinembedded tumor samples: Utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol 2007; 31: 1476-1489. (Pubitemid 47482460)
100. Muthusamy V, Hobbs C, Nogueira C, Cordon-Cardo C, McKee PH, Chin L et al. Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer 2006; 45: 447-454.
101. Forslund A, Zeng ZS, Qin LX, Rosenberg S, Ndubuisi M, Pincas H et al. MDM2 gene amplification is correlated to tumor progression but not to the presence of SNP309 or TP53 mutational status in primary colorectal cancers. Mol Cancer Rese 2008; 6: 205-211. (Pubitemid 351342408)
102. Riemenschneider MJ, Buschges R, Wolter M, Reifenberger J, Bostrom J, Kraus JA et al. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res 1999; 59: 6091-6096. (Pubitemid 30035626)
103. Danovi D, Meulmeester E, Pasini D, Migliorini D, Capra M, Frenk R et al. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol 2004; 24: 5835-5843. (Pubitemid 38787968)
104. Laurie NA, Donovan SL, Shih CS, Zhang JK, Mills N, Fuller C et al. Inactivation of the p53 pathway in retinoblastoma. Nature 2006; 444: 61-66. (Pubitemid 44684754)
105. Dal Bo M, Secchiero P, Degan M, Marconi D, Bomben R, Pozzato G et al. MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild-type CLL with a poor cytotoxic response to Nutlin-3. Br J Haematol 2010; 150: 237-239.
106. Ray-Coquard I, Blay JY, Italiano A, Le Cesne A, Penel N, Zhi J et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-ofmechanism study. Lancet Oncol 2012; 13: 1133-1140.
107. Dommering CJ, Marees T, van der Hout AH, Imhof SM, Meijers-Heijboer H, Ringens PJ et al. RB1 mutations and second primary malignancies after hereditary retinoblastoma. Familial Cancer 2012; 11: 225-233.
108. Berge EO, Knappskog S, Geisler S, Staalesen V, Pacal M, Borresen-Dale AL et al. Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers. Mol Cancer 2010; 9: 173.
109. Witkiewicz AK, Ertel A, McFalls J, Valsecchi ME, Schwartz GG, Knudsen ES. RBpathway disruption is associated with improved response to neoadjuvant therapy in breast cancer. Clin Cancer Res 2012; 18: 5110-5122.
110. Berge EO, Knappskog S, Lillehaug JR, Lonning PE. Alterations of the retinoblastoma gene in metastatic breast cancer. Clin Exp Metastasis 2011; 28: 319-326.
111. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 2008; 8: 671-682.
112. Akakura S, Nochajski P, Gao LQ, Sotomayor P, Matsui S, Gelman IH. Rb-dependent cellular senescence, multinucleation and susceptibility to oncogenic transformation through PKC scaffolding by SSeCKS/AKAP12. Cell Cycle 2010; 9: 4656-4665.
113. Knudsen ES, Knudsen KE. Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer 2008; 8: 714-724.
114. Ianari A, Natale T, Calo E, Ferretti E, Alesse E, Screpanti I et al. Proapoptotic function of the retinoblastoma tumor suppressor protein. Cancer Cell 2009; 15: 184-194.
115. Bowen C, Spiegel S, Gelmann EP. Radiation-induced apoptosis mediated by retinoblastoma protein. Cancer Res 1998; 58: 3275-3281. (Pubitemid 28371065)
116. Almasan A, Yin YX, Kelly RE, Lee E, Bradley A, Li WW et al. Deficiency of retinoblastoma protein leads to inappropriate s-phase entry, activation of e2fresponsive genes, and apoptosis. Proc Natl Acad Sci USA 1995; 92: 5436-5440.
117. Knudsen KE, Booth D, Naderi S, Sever-Chroneos Z, Fribourg AF, Hunton IC et al. RB-dependent S-phase response to DNA damage. Mol Cell Biol 2000; 20: 7751-7763.
118. Zagorski WA, Knudsen ES, Reed MF. Retinoblastoma deficiency increases chemosensitivity in lung cancer. Cancer Res 2007; 67: 8264-8273. (Pubitemid 47395164)
119. Bosco EE, Wang Y, Xu H, Zilfou JT, Knudsen KE, Aronow BJ et al. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest 2007; 117: 218-228. (Pubitemid 46048468)
120. Sharma A, Comstock CES, Knudsen ES, Cao KH, Hess-Wilson JK, Morey LM et al. Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Cancer Res 2007; 67: 6192-6203. (Pubitemid 47037500)
121. Derenzini M, Brighenti E, Donati G, Vici M, Ceccarelli C, Santini D et al. The p53-mediated sensitivity of cancer cells to chemotherapeutic agents is conditioned by the status of the retinoblastoma protein. J Pathol 2009; 219: 373-382.
122. Leontieva OV, Gudkov AV, Blagosklonny MV. Weak p53 permits senescence during cell cycle arrest. Cell Cycle 2010; 9: 4323-4327.
123. Lin WC, Lin FT, Nevins JR. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Gene Dev 2001; 15: 1833-1844. (Pubitemid 32905640)
124. Stevens C, Smith L, La Thangue NB. Chk2 activates E2F-1 in response to DNA damage. Nat Cell Biol 2003; 5: 401-409. (Pubitemid 36592262)
125. Pediconi N, Ianari A, Costanzo A, Belloni L, Gallo R, Cimino L et al. Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nat Cell Biol 2003; 5: 552-558. (Pubitemid 36781090)
126. Powers JT, Hong SK, Mayhew CN, Rogers PM, Knudsen ES, Johnson DG. E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis. Mol Cancer Res 2004; 2: 203-214. (Pubitemid 39031081)
127. Eldeiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825. (Pubitemid 23346378)
128. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182. (Pubitemid 17231334)
129. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712. (Pubitemid 19147683)
130. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer Jr CE, Davidson NE et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684. (Pubitemid 41464706)
131. Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 2012; 30: 2585-2592.
132. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-119.
133. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F et al. c-erB-2 expression and response to adjuvant therapy in women with node-positive early Breast cancer. N Engl J Med 1994; 330: 1260-1266.
134. Paik SM, Bryant J, Park CH, Fisher B, TanChiu E, Hyams D et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998; 90: 1361-1370. (Pubitemid 28439960)
135. Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006; 354: 2103-2111. (Pubitemid 43736610)
136. Petit T, Borel C, Ghnassia J-P, Rodier J-F, Escande A, Mors R et al. Chemotherapy response of breast cancer depends on HER-status and antracycline dose intensity in the neoadjuvant setting. Clin Cancer Res 2001; 7: 1577-1581. (Pubitemid 32708622)
137. Press MF, Bernstein L, Sauter G, Zhou JY, Eiermann W, Pienkowski T et al. Topoisomerase II-alpha gene amplification as a predictor of responsiveness to anthracycline-containing chemotherapy in the Cancer International Research Group 006 clinical trial of trastuzumab (herceptin) in the adjuvant setting. Breast Cancer Res Treat 2005; 94: S54-S54.
138. Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005; 23: 7483-7490. (Pubitemid 46291811)
139. Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmstrom P et al. Topoisomerase II alpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 2006; 24: 2428-2436. (Pubitemid 46630618)
140. O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 2009; 101: 644-650.
141. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997; 15: 537-547. (Pubitemid 27384731)
142. Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009; 27: 1168-1176.
143. Baselga J. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist 2011; 16: 12-19.
144. Lachlan KL, Lucassen AM, Bunyan D, Temple IK. Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: results of a clinical study of PTEN mutation carriers. J Med Genet 2007; 44: 9.
145. Riviere JB, Mirzaa GM, O'Roak BJ, Beddaoui M, Alcantara D, Conway RL et al. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat Genet 2012; 44: 934.
146. Orloff MS, He X, Peterson C, Chen FS, Chen JL, Mester JL et al. Germline PIK3CA and AKT1 Mutations in Cowden and Cowden-like Syndromes. Am J Hum Gen 2013; 92: 76-80.
147. Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J Clin Oncol 2008; 26: 1059-1065.
148. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009; 27: 5529-5537.
149. Johnston S, Pippen J, Pivot X, Lichinitser M, Sadeghi S, Dieras V et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27: 5538-5546.
150. DeGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res 2004; 10: 8059-8067. (Pubitemid 39587547)
151. Beeram M, Tan QTN, Tekmal RR, Russell D, Middleton A, Degraffenried LA. Aktinduced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 2007; 18: 1323-1328. (Pubitemid 47305004)
152. Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520-529.
153. Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G et al. Randomized phase ii trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012; 30: 2718-2724.
154. Bukowski RM. Temsirolimus: a safety and efficacy review. Expert Opin Drug Saf 2012; 11: 861-879.
155. Diaz-Padilla I, Duran I, Clarke BA, Oza AM. Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer. Cancer Treat Rev 2012; 38: 767-775.
156. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006; 94: 455-459. (Pubitemid 43289745)
157. Russnes HG, Navin N, Hicks J, Borresen-Dale AL. Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest 2011; 121: 3810-3818.
158. Bleeker FE, Felicioni L, Buttitta F, Lamba S, Cardone L, Rodolfo M et al. AKT1(E17K) in human solid tumours. Oncogene 2008; 27: 5648-5650.
159. Schmitz KJ, Otterbach F, Callies R, Levkau B, Holscher M, Hoffmann O et al. Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases. Mod Pathol 2004; 17: 15-21. (Pubitemid 41656447)
160. Aleskandarany MA, Rakha EA, Ahmed MA, Powe DG, Ellis IO, Green AR. Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer. Breast Cancer Res Treatment 2011; 127: 407-416.
161. Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A et al. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 2005; 207: 139-146. (Pubitemid 41404144)
162. Wendel HG, de Stanchina E, Fridman JS, Malina A, Ray S, Kogan S et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428: 332-337. (Pubitemid 38418805)
163. Yunokawa M, Koizumi F, Kitamura Y, Katanasaka Y, Okamoto N, Kodaira M et al. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells. Cancer Sci 2012; 103: 1665-1671.
164. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002; 62: 6141-6145. (Pubitemid 35244463)
165. Zhang XB, Zhang S, Liu Y, Liu JJ, Ma Y, Zhu YX et al. Effects of the combination of RAD001 and docetaxel on breast cancer stem cells. Eur J Cancer 2012; 48: 1581-1592.
166. Xue YW, Chen J, Choi HH, Phan L, Chou PC, Zhao RY et al. HER2-Akt signaling in regulating COP9 signalsome subunit 6 and p53. Cell Cycle 2012; 11: 4181-4190.
167. Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmana J et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov 2012; 2: 1048-1063.
168. Shen WH, Balajee AS, Wang JL, Wu H, Eng C, Pandolfi PP et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007; 128: 157-170. (Pubitemid 46048887)
169. Freeman DJ, Li AG, Wei G, Li HH, Kertesz N, Lesche R et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and-independent mechanisms. Cancer Cell 2003; 3: 117-130. (Pubitemid 37443385)
170. Trotman LC, Pandolfi PP. PTEN and p53: Who will get the upper hand? Cancer Cell 2003; 3: 97-99. (Pubitemid 37443380)
171. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 2001; 98: 11598-11603. (Pubitemid 32928774)
172. Ashcroft M, Ludwig RL, Woods DB, Copeland TD, Weber HO, MacRae EJ et al. Phosphorylation of HDM2 by Akt. Oncogene 2002; 21: 1955-1962. (Pubitemid 34270884)
173. Ogawara Y, Kishishita S, Obata T, Isazawa Y, Suzuki T, Tanaka K et al. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 2002; 277: 21843-21850. (Pubitemid 34952337)
174. Gottlieb TM, Leal JFM, Seger R, Taya Y, Oren M. Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene 2002; 21: 1299-1303. (Pubitemid 34185247)
175. Ali IU, Schriml LM, Dean M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 1999; 91: 1922-1932.
176. Nagata Y, Lan KH, Zhou XY, Tan M, Esteva FJ, Sahin AA et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6: 117-127. (Pubitemid 39485684)
177. Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PLM et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 1999; 155: 1253-1260. (Pubitemid 29488932)
178. Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 2001; 14: 672-676. (Pubitemid 32667211)
179. Garcia JM, Silva J, Pena C, Garcia V, Rodriguez R, Cruz MA et al. Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer 2004; 41: 117-124. (Pubitemid 39096737)
180. Zysman MA, Chapman WB, Bapat B. Considerations when analyzing the methylation status of PTEN tumor suppressor gene. Am J Pathol 2002; 160: 795-800. (Pubitemid 34224569)
181. Poliseno L, Salmena L, Zhang JW, Carver B, Haveman WJ, Pandolfi PP. A codingindependent function of gene and pseudogene mRNAs regulates tumour biology. Nature 2010; 465: 1033-U90.
182. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the rosetta stone of a hidden RNA language? Cell 2011; 146: 353-358.
183. Viktorsson K, De Petris L, Lewensohn R. The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun 2005; 331: 868-880. (Pubitemid 40615518)
184. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature 2012; 481: 287-294.
185. Martin SA, Lord CJ, Ashworth A. DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev 2008; 18: 80-86. (Pubitemid 351694447)
186. Zhang HB, Somasundaram K, Peng Y, Tian H, Zhang HX, Bi DK et al. BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 1998; 16: 1713-1721. (Pubitemid 28175052)
187. Zurer I, Hofseth LJ, Cohen Y, Xu-Welliver M, Hussain SP, Harris CC et al. The role of p53 in base excision repair following genotoxic stress. Carcinogenesis 2004; 25: 11-19. (Pubitemid 38139225)
188. Chen JG, Sadowski I. Identification of the mismatch repair genes PMS2 and MLH1 as p53 target genes by using serial analysis of binding elements. Proc Natl Acad Sci USA 2005; 102: 4813-4818. (Pubitemid 40471536)
189. Bhana S, Hewer A, Phillips DH, Lloyd DR. p53-dependent global nucleotide excision repair of cisplatin-induced intrastrand cross links in human cells. Mutagenesis 2008; 23: 131-136.
190. Wang XW, Vermeulen W, Coursen JD, Gibson M, Lupold SE, Forrester K et al. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev 1996; 10: 1219-1232. (Pubitemid 26171103)
191. Hwang BJ, Ford JM, Hanawalt PC, Chu G. Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. Proc Natl Acad Sci USA 1999; 96: 424-428. (Pubitemid 29061224)
192. Williams SA, Wilson JB, Clark AP, Mitson-Salazar A, Tomashevski A, Ananth S et al. Functional and physical interaction between the mismatch repair and FA-BRCA pathways. Hum Mol Genet 2011; 20: 4395-4410.
193. Romeo F, Falbo L, Di Sanzo M, Misaggi R, Faniello MC, Viglietto G et al. BRCA1 is required for hMLH1 stabilization following doxorubicin-induced DNA damage. Int J Biochem Cell Biol 2011; 43: 1754-1763.
194. Foray N, Marot D, Gabriel A, Randrianarison V, Carr AM, Perricaudet M et al. A subset of ATM-and ATR-dependent phosphorylation events requires the BRCA1 protein. EMBO J 2003; 22: 2860-2871. (Pubitemid 36712381)
195. Norgauer J, Idzko M, Panther E, Hellstern O, Herouy Y. Xeroderma pigmentosum. Eur J Dermatol 2003; 13: 4-9. (Pubitemid 36228497)
196. Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer 2001; 1: 22-33. (Pubitemid 33741878)
197. Wang QE, Milum K, Han CH, Huang YW, Wani G, Thomale J et al. Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells. Mol Cancer 2011; 10.
198. Reardon JT, Vaisman A, Chaney SG, Sancar A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichloro- cyclohexylamine-platinum( IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 1999; 59: 3968-3971. (Pubitemid 29393563)
199. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 1992; 84: 1512-1517.
200. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16: 309-316. (Pubitemid 28041614)
201. Park JS, Jeon EK, Chun SH, Won HS, Lee A, Hur SY et al. ERCC1 (excision repair cross-complementation group 1) expression as a predictor for response of neoadjuvant chemotherapy for FIGO stage 2B uterine cervix cancer. Gynecol Oncol 2011; 120: 275-279.
202. Tsai CM, Chang KT, Li L, Perng RP, Yang LY. Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER-2/neu gene expression, and epidermal growth factor receptor level in non-small cell lung cancer cells. Jpn J Cancer Res 2000; 91: 213-222. (Pubitemid 30130752)
203. Hsu DSS, Lan HY, Huang CH, Tai SK, Chang SY, Tsai TL et al. Regulation of excision repair cross-complementation group 1 by snail contributes to cisplatin resistance in head and neck cancer. Clin Cancer Res 2010; 16: 4561-4571.
204. Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004; 10: 4939-4943. (Pubitemid 39099767)
205. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ. A. Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001; 61: 8654-8658. (Pubitemid 34013872)
206. Santonocito C, Scapaticci M, Penitente R, Paradisi A, Capizzi R, Lanza-Silveri S et al. Polymorphisms in base excision DNA repair genes and association with melanoma risk in a pilot study on Central-South Italian population. Clin Chim Acta 2012; 413: 1519-1524.
207. Yang J, Parsons J, Nicolay NH, Caporali S, Harrington CF, Singh R et al. Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy. Oncogene 2010; 29: 463-468.
208. van der Kolk DM, de Bock GH, Leegte BK, Schaapveld M, MJE Mourits, de Vries J et al. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat 2010; 124: 643-651.
209. Evans DG, Shenton A, Woodward E, Lalloo F, Howell A, Maher ER. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer 2008; 8: 155.
210. Rafnar T, Gudbjartsson DF, Sulem P, Jonasdottir A, Sigurdsson A, Besenbacher S et al. Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet 2011; 43: 1104-U91.
211. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007; 39: 165-167. (Pubitemid 46184346)
212. Somyajit K, Subramanya S, Nagaraju G. Distinct roles of Fanco/RAD51C protein in DNA damage signaling and repair implications for fanconi anemia and breast cancer susceptibility. J Biol Chem 2012; 287: 3366-3380.
213. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA 2011; 108: 18032-18037.
214. Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, Frankum JR et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 2011; 43: 879-U90.
215. Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010; 42: 410-U65.
216. Valeri A, Martinez S, Casado JA, Bueren JA. Fanconi anaemia: from a monogenic disease to sporadic cancer. Clin Transl Oncol 2011; 13: 215-221.
217. Garcia MJ, Benitez J. The Fanconi anaemia/BRCA pathway and cancer susceptibility: searching for new therapeutic targets. Clin Transl Oncol 2008; 10(2): 78-84.
218. Cheang MCU, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value then triple-negative phenotype. Clin Cancer Res 2008; 14: 1368-1376. (Pubitemid 351413917)
219. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009; 15: 2302-2310.
220. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
221. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-2334. (Pubitemid 46698581)
222. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-5685. (Pubitemid 41170290)
223. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010; 28: 1145-1153.
224. Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 2008; 19: 1847-1852.
225. Young SR, Pilarski RT, Donenberg T, Shapiro C, Hammond LS, Miller J et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 2009; 9: 86.
226. Arun B, Bayraktar S, Liu DD, Barrera AMG, Atchley D, Pusztai L et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol 2011; 29: 3739-3746.
227. Kriege M, Seynaeve C, Meijers-Heijboer H, Collee JM, Menke-Pluymers MBE, Bartels CCM et al. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009; 27: 3764-3771.
228. Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK et al. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat 2011; 130: 145-153.
229. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010; 28: 375-379.
230. Gronwald J, Byrski T, Huzarski T, Dent R, Bielicka V, Zuziak D et al. Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. J Clin Oncol 2009; 27(Suppl 155): 7.
231. Kriege M, Jager A, Hooning MJ, Huijskens E, Blom J, van Deurzen CHM et al. The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer 2012; 118: 899-907.
232. Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat F. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 2006; 5: 1001-1007.
233. Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J et al. BRCA mutation frequency and patterns of treatment response in BRCA mutationpositive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012; 30: 2654-2663.
234. Eisenhauer EA, Vermorken JB, vanGlabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 1997; 8: 963-968. (Pubitemid 27475726)
235. Tan DSP, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S et al. 'BRCAness' syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008; 26: 5530-5536.
236. Vencken P, Kriege M, Hoogwerf D, Beugelink S, van der Burg MEL, Hooning MJ et al. Chemosensitivity and outcome of BRCA1-and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol 2011; 22: 1346-1352.
237. Dann RB, DeLoia JA, Timms KM, Zorn KK, Potter J, Flake DD et al. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol 2012; 125: 677-682.
238. Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. J Am Med Assoc 2011; 306: 1557-1565.
239. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008; 451: 1111-1115. (Pubitemid 351317441)
240. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008; 451: 1116-U9.
241. Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 2011; 29: 3008-3015.
242. Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 2008; 68: 2581-2586. (Pubitemid 351556255)
243. Smiraldo PG, Gruver AM, Osborn JC, Pittman DL. Extensive chromosomal instability in Rad51d-deficient mouse cells. Cancer Res 2005; 65: 2089-2096. (Pubitemid 40490114)
244. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH. Integrating genetic approaches into the discovery of anticancer drugs. Science 1997; 278: 1064-1068. (Pubitemid 27517876)
245. Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921. (Pubitemid 40559006)
246. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-917. (Pubitemid 40559005)
247. Rehman FL, Lord CJ, Ashworth A. Synthetic lethal approaches to breast cancer therapy. Nat Rev Clin Oncol 2010; 7: 718-724.
248. Dworkin AM, Spearman AD, Tseng SY, Sweet K, Toland AE. Methylation not a frequent 'second hit' in tumors with germline BRCA mutations. Fam Cancer 2009; 8: 339-346.
249. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.
250. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; 28: 2512-2519.
251. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 245-251.
252. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235-244.
253. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, openlabel, non-randomised study. Lancet Oncol 2011; 12: 852-861.
254. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366: 1382-1392.
255. Hennessy BTJ, Timms KM, Carey MS, Gutin A, Meyer LA, Flake II DD et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP Ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 2010; 28: 3570-3576.
256. Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F et al. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
257. Moskwa P, Buffa FM, Pan YF, Panchakshari R, Gottipati P, Muschel RJ et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell 2011; 41: 210-220.
258. Garcia AI, Buisson M, Bertrand P, Rimokh R, Rouleau E, Lopez BS et al. Downregulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol Med 2011; 3: 279-290.
259. Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S, Maitra A et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther 2011; 10: 3-8.
260. Hastak K, Alli E, Ford J. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine and cisplatin. Cancer Res 2010; 70: 7970-7980.
261. O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364: 205-214.
262. O'Shaugnessy J. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative brerast cancer (TNBC). J Clin Oncol (Suppl) 2011; 29: 15S-18S.
263. Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res 2012; 18: 1655-1662.
264. Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle 2011; 10: 1192-1199.
265. Liu XS, Han EK, Anderson M, Shi Y, Semizarov D, Wang G et al. Acquired resistance to combination treatment with temozolomide and ABT-888 Is mediated by both base excision repair and homologous recombination DNA repair pathways. Mol Cancer Res 2009; 7: 1686-1692.
266. Domagala P, Huzarski T, Lubinski J, Gugala K, Domagala W. PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy. Breast Cancer Res Treat 2011; 127: 861-869.
267. von Minckwitz G, Muller BM, Loibl S, Budczies J, Hanusch C, Darb-Esfahani S et al. Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 2011; 29: 2150-2157.
268. Kerzendorfer C, O'Driscoll M. Human DNA damage response and repair deficiency syndromes: linking genomic instability and cell cycle checkpoint proficiency. DNA Repair 2009; 8: 1139-1152.
269. Fu YP, Yu JC, Cheng TC, Lou MA, Hsu GC, Wu CY et al. Breast cancer risk associated with genotypic polymorphism of the nonhomologous end-joining genes: a multigenic study on cancer susceptibility. Cancer Res 2003; 63: 2440-2446. (Pubitemid 36605181)
270. Merel P, Prieur A, Pfeiffer P, Delattre O. Absence of major defects in nonhomologous DNA end joining in human breast cancer cell lines. Oncogene 2002; 21: 5654-5659. (Pubitemid 34983556)
271. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 2009; 76: 1-18.
272. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracilbased adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-257. (Pubitemid 36859476)
273. Vasen H, Watson PH, Mecklin J-P, Lynch H. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 1999; 116: 1453-1456. (Pubitemid 29258894)
274. Honecker F, Wermann H, Mayer F, Gillis AJM, Stoop H, van Gurp R et al. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol 2009; 27: 2129-2136.
275. Martin SA, McCarthy A, Barber LJ, Burgess DJ, Parry S, Lord CJ et al. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol Med 2009; 1: 323-337.
276. Diouf B, Cheng Q, Krynetskaia NF, Yang WJ, Cheok M, Pei DQ et al. Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nat Med 2011; 17: 1298-U332.
277. Kaina B, Christmann M, Naumann S, Roos WP. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair 2007; 6: 1079-1099. (Pubitemid 47058389)
278. Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004; 10: 4933-4938. (Pubitemid 39099766)
279. Balana C, Ramirez JL, Taron M, Roussos Y, Ariza A, Ballester R et al. O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res 2003; 9: 1461-1468. (Pubitemid 36418402)
280. Hegi ME, Diserens A, Gorlia T, Hamou M, de Tribolet N, Weller M et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003. (Pubitemid 40349502)
281. Sjøblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314: 268-274. (Pubitemid 44571966)
282. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G et al. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446: 153-158. (Pubitemid 46398669)
283. Castillo P, Bogliolo M, Surralles J. Coordinated action of the Fanconi anemia and ataxia telangiectasia pathways in response to oxidative damage. DNA Repair 2011; 10: 518-525.
284. Ibrahim YH, Garcia-Garcia C, Serra V, He L, Torres-Lockhart K, Prat A et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triplenegative breast cancer to PARP-inhibition. Cancer Discovery 2012; 2: 1036-1047.